Eton Pharmaceuticals beats Q4 adjusted EPS estimates

Overview

• U.S. rare disease drugmaker's Q4 product sales rose 83% yr/yr, driven by new launches

• Adjusted EPS for Q4 beat analyst expectations

• Company launched DESMODA and acquired U.S. rights to HEMANGEOL, both expected to drive growth

Outlook

• Eton expects 2026 revenue to exceed $110 mln

• Company sees 2026 Adjusted EBITDA margin of at least 30%

• Company expects DESMODA and HEMANGEOL to be key growth contributors in 2026

Result Drivers

• NEW PRODUCT LAUNCHES - Q4 sales growth driven by addition of INCRELEX, GALZIN, and KHINDIVI, as well as strong growth in ALKINDI SPRINKLE

• R&D expenses for the fourth quarter of 2025 were $1.8 million compared to loss of $0.9 million in the prior year period

Company press release: ID:nGNX1ldZw4

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $30.00, about 57.7% above its March 18 closing price of $19.02

• The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 15 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.